Clinical & Experimental Ophthalmology

Cover image for Vol. 45 Issue 2

Edited By: Robert Casson and Salmaan Al-Qureshi

Impact Factor: 2.546

ISI Journal Citation Reports © Ranking: 2015: 16/56 (Ophthalmology)

Online ISSN: 1442-9071

Associate Professor Salmaan Al-Qureshi Bio

Dr Salmaan Al-Quershi Bio

Salmaan Al-Qureshi MBBS FRANZCO

Centre for Eye Research Australia, University of Melbourne

Salmaan Al-Qureshi is Co-Editor-in-Chief of Clinical and Experimental Ophthalmology, Fellow at the Centre for Eye Research Australia (at the University of Melbourne) and Senior Consultant Ophthalmologist at the Royal Victorian Eye and Ear Hospital. He is a former board member of the Ophthalmic Research Institute of Australia, and served on the program committee for the annual RANZCO scientific congress from 2002 to 2006.

He is author of the “Interactive Atlas of Retinal Disease” for the Apple iPad and iPhone.

Associate Professor Al-Qureshi trained in medicine at the University of Adelaide. His ophthalmology residency training was at Flinders Medical Centre (Professor DJ Coster) and the Royal Adelaide Hospital.  His first fellowship in anterior segment reconstruction and corneal transplantation was at the Leeds General Infirmary. In 2000 he was selected as medical retina fellow to Professor Alan Bird at Moorfields Eye Hospital for his second sub-specialist fellowship.

Associate Professor Al-Qureshi returned to Australia from the United Kingdom to take up a consultant post in the Medical Retina Unit of the Royal Victorian Eye & Ear Hospital. Since then, he has been involved in clinical work and teaching at the institution. Over the last 10 years he has been involved in the clinical testing and development of the new generation of anti-VEGF treatments that are now central to the management of retinal disease including Macugen, Lucentis and Avastin.

He was the principal investigator in the first Australian trial of Avastin for retinal disease in 2005. This trial provided the foundation for the introduction of Avastin treatment throughout Australia. His current area of research (at the Centre for Eye Research Australia) is the role of lipids and retinal vascular calibre in the pathogenesis of retinal vascular disease.

Associate Professor Al-Qureshi is secretary to the Victorian Qualification & Education Committee which has responsibility for the selection and training of ophthalmology registrars in Victoria.

Competing interests: None

Financial disclosure:

Editor in Chief of CEO: Significant advertising from Novartis, Bayer, Alcon, Allergen, Abbott pharmaceuticals.

Public Health Services- Reportable Disclosures: Royal Victorian Eye & Ear Hospital: Senior Consultant 2001- current. The Medical Retina Service employs 2 Novartis funded Retina Fellows and one Bayer funded Fellow.

Centre for Eye Research Australia at the University of Melbourne (Associate Professor): Principal investigator, Associate Investigator for a number of industry sponsored clinical trials for Novartis, Regerneron, Bayer, Genentech, Alcon and Allergan. These are/were unpaid, but include travel support to investigator meetings, and presentations at peer reviewed conferences.

Eye Surgery Associates: Principal Associate

Medina Systems: Software developer & Author of the Retina Atlas for iPad & iPhone

No industry medical advisory board appointments, industry consultancies, speaking fees or industry stocks.